Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)	Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, squamous cell carcinoma, squamous cell neoplasm	Active, not recruiting	Phase 2	2026-07-16		NCT04808999

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Diwakar Davar	6
Merck Sharp & Dohme LLC	650

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
UPMC Hillman Cancer Center	Pittsburgh	United States	330

Clinical trials